Clinical Trials Logo

Thymoma clinical trials

View clinical trials related to Thymoma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04371458 Withdrawn - Stage IVA Thymoma Clinical Trials

Thymectomy With and Without Povidone-iodine Pleural Lavage in Stage IVA Thymic Malignancies

Start date: July 2020
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate whether intraoperative pleural lavage with providone-iodine following complete resection and pleural reductive surgery for stage IVA thymoma reduces recurrent rates compared to surgery without providone-iodine lavage

NCT ID: NCT02948855 Withdrawn - Thymoma Clinical Trials

Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases

Start date: October 2016
Phase:
Study type: Observational

Initially investigators will find LncRNA which to be able to affect Notch2 signaling pathway; then confirm the relationship between Notch2 and LncRNA, and analysis the regulation mode of LncRNA to Notch2 signaling pathway, and to observe the correlation between LncRNA and thymoma complicated with autoimmune diseases.

NCT ID: NCT01610544 Withdrawn - Clinical trials for Carcinoma, Non-Small-Cell Lung

18F FLT Imaging Studies of Treatment Response for Lung Cancer and Thymoma

Start date: May 10, 2012
Phase: Phase 2
Study type: Interventional

Background: - Imaging studies like positron emission tomography (PET) and computed tomography (CT) scans are used to detect tumor responses to cancer treatment. However, it may be difficult to detect early response to lung cancer or thymoma treatment with standard PET/CT scans. These scans cannot easily show a difference between remaining cancer cells and inflammation. Researchers want to try a new PET/CT scan tracer that may be able to show the difference between these cells. 18F-Fluorothymidine (18F-FLT) is better at showing which cells are still actively dividing. PET/CT scans with 18F-FLT may help show if tumor cells are responding to early stages of treatment. Objectives: - To see if 18F-FLT is a safe and effective imaging study tracer to show early cancer response to treatment. Eligibility: - Individuals at least 18 years of age who are being treated for lung cancer or thymoma. Design: - Participants will be screened with a physical exam and medical history. Blood, urine, and tumor tissue samples will be collected. - Participants will have two PET/CT scans on separate days before starting chemotherapy. One scan will be with a standard radiotracer. The other will be with the 18F-FLT tracer. - About 2 weeks after starting chemotherapy, participants will repeat the two PET/CT scans on separate days. Additional blood samples will be collected at this time.